New antiviral candidate capable of inhibiting a broad range of highly contagious coronaviruses
The World Health Organization (WHO) has concluded that the Middle East respiratory syndrome (MERS) outbreak that has been ravaging Saudi Arabia is finally abating. However, this certainly doesn't mean the virus is no longer a threat.
A case of camel-to-human infection of Middle East respiratory syndrome (MERS) has been identified, confirming the theory that the pack animals are the source of the deadly virus.
Following an investigation of potential Middle Eastern respiratory syndrome (MERS) cases since 2012, the Saudi Arabian Health Ministry has revised its number of total cases. As of May 2, the total number of MERS-Cov related deaths seen in Saudi Arabia has increased to 282.
Severe acute respiratory syndrome (SARS) and Middle East reparatory syndrome (MERS) both continue to have no known cure or vaccination, despite the fact that the viruses have proven deadly in some cases. Now, scrambling researchers have identified a compound that renders viruses such as MERS harmless, unable to inflict damage to human cells or reproduce, according to a recent study.
An experimental compound that has been shown to effectively treat Severe Acute Respiratory Syndrome (SARS) may also work equally well in treating Middle East respiratory syndrome (MERS), a new study suggests. This same drug has even proven effective at treating a hepatitis virus in mice (MHV), causing researchers to suspect that it could be used to target a broad spectrum of coronaviruses, despite subtle differences in how they present themselves.
A French patient infected with a deadly new respiratory virus related to SARS died Tuesday of the disease, which has already killed 22 of its 44 known victims, the Associated Press reported.